Your browser doesn't support javascript.
loading
ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer.
de Oliveira Cavagna, Rodrigo; Zaniolo, Beatriz Garbe; de Paula, Flávia Escremim; Berardinelli, Gustavo Noriz; Santana, Iara; da Silva, Eduardo Caetano Albino; Dias, Josiane Mourão; Jacinto, Alexandre Arthur; da Nóbrega Oliveira, Rachid Eduardo Noleto; de Marchi, Pedro; Leal, Letícia Ferro; Reis, Rui Manuel.
Afiliación
  • de Oliveira Cavagna R; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • Zaniolo BG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • de Paula FE; Barretos School of Health Sciences Dr. Paulo Prata - FACISB, Barretos, Brazil.
  • Berardinelli GN; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
  • Santana I; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.
  • da Silva ECA; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
  • Dias JM; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
  • Jacinto AA; Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil.
  • da Nóbrega Oliveira REN; Deparment of Radiology, Barretos Cancer Hospital, Barretos, Brazil.
  • de Marchi P; Deparment of Thoracic Surgery, Barretos Cancer Hospital, Barretos, Brazil.
  • Leal LF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.
  • Reis RM; Oncoclinicas, Rio de Janeiro, Brazil.
Thorac Cancer ; 13(23): 3402-3407, 2022 12.
Article en En | MEDLINE | ID: mdl-36251951
ERBB2 exon 20 insertions may impact the clinical management of lung cancer patients. However, the frequency of ERBB2 exon 20 insertions in lung cancer patients in Brazil is scarce. Here, we analyzed 722 Brazilian non-small cell lung cancer (NSCLC) patients from Barretos Cancer Hospital that were indicated to require routine lung cancer molecular testing. ERBB2 exon 20 insertions were evaluated by a targeted panel using next-generation sequencing (NGS). Clinicopathological and molecular data were collected from patient medical records. Among the 722 NSCLC patients, 85.2% had lung adenocarcinomas, 53.9% were male, 66.8% were quitter or current smokers, and 63.2% were diagnosed at an advanced stage of the disease. We identified 0.8% (6/722) of patients who harbored the insertion p.(Tyr772_Ala775dup) at exon 20 of the ERBB2 gene. All ERBB2 mutated patients were diagnosed with lung adenocarcinoma, were never smokers, and wild-type for EGFR, KRAS, and ALK hotspot alterations. Less than 1% of Brazilian NSCLC patients harbor ERBB2 exon 20 insertions, yet they could benefit in future from the new drugs in development.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Female / Humans / Male País/Región como asunto: America do sul / Brasil Idioma: En Revista: Thorac Cancer Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Singapur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Adenocarcinoma del Pulmón / Neoplasias Pulmonares Límite: Female / Humans / Male País/Región como asunto: America do sul / Brasil Idioma: En Revista: Thorac Cancer Año: 2022 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Singapur